Emmaus Life Sciences Inc (EMMA)
OTHER OTC:EMMA
EMMA Stock Chart & Stats
$0.01
<$0.01(41.41%)
At close: 4:00 PM EST
$0.01
<$0.01(41.41%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume11.42K
Average Volume (3M)112.45K
Market Cap
$701.88K
Enterprise Value$31.07M
Total Cash (Recent Filing)$2.13M
Total Debt (Recent Filing)$32.56M
Price to Earnings (P/E)―
Beta58.72
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding70,188,260
10 Day Avg. Volume152,781
30 Day Avg. Volume112,453
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.01
Price to Sales (P/S)0.07
P/FCF Ratio-69.38
Enterprise Value/Market Cap44.27
Enterprise Value/Revenue2.50
Enterprise Value/Gross Profit2.68
Enterprise Value/Ebitda-100.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained very high gross margins indicate durable product-level economics and pricing power for the core L-glutamine therapy. Over months this supports ability to cover fixed costs, fund targeted R&D or manufacturing scale, and make margin-based supply deals more financially meaningful.
Exclusive Endari Supply AgreementA binding supply arrangement (conditional on license effectiveness) structurally shifts Emmaus toward a manufacturing/supply role with predictable margin per unit. If consummated, this reduces commercial spend, stabilizes revenue mix toward margin-based supply, and leverages manufacturing capability long-term.
Focused Orphan-disease FranchiseConcentration on sickle cell and orphan indications creates specialist expertise, clearer regulatory pathways, and targetable payer relationships. Structural demand in rare-disease niches can sustain pricing and allow efficient resource allocation to a narrow product set over the medium term.
Bears Say
Deeply Negative EquityPersistently negative equity reflects accumulated losses and a weakened capital base, constraining balance-sheet flexibility. Over coming months this raises refinancing and dilution risk, limits borrowing capacity, and impairs ability to invest in scale or absorb commercial setbacks without external funding.
Consistent Negative Operating Cash FlowOngoing negative operating cash flow shows the business is not self-funding and remains dependent on external capital. Even with TTM burn near breakeven, the historical pattern of large outflows increases funding risk and may force dilutive financing or constrain strategic investments over the medium term.
Revenue Volatility And DeclinesMarked revenue declines and volatility undermine predictability of earnings and make fixed-cost absorption harder. Structural uncertainty in demand for the core product complicates planning, stresses margins at lower volumes, and increases reliance on partner deals or approvals to restore stable revenue streams.
Emmaus Life Sciences News
EMMA FAQ
What was Emmaus Life Sciences Inc’s price range in the past 12 months?
Emmaus Life Sciences Inc lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Emmaus Life Sciences Inc’s market cap?
Emmaus Life Sciences Inc’s market cap is $701.88K.
When is Emmaus Life Sciences Inc’s upcoming earnings report date?
Emmaus Life Sciences Inc’s upcoming earnings report date is May 20, 2026 which is in 40 days.
How were Emmaus Life Sciences Inc’s earnings last quarter?
Emmaus Life Sciences Inc released its earnings results on Mar 31, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.03.
Is Emmaus Life Sciences Inc overvalued?
According to Wall Street analysts Emmaus Life Sciences Inc’s price is currently Overvalued.
Does Emmaus Life Sciences Inc pay dividends?
Emmaus Life Sciences Inc does not currently pay dividends.
What is Emmaus Life Sciences Inc’s EPS estimate?
Emmaus Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emmaus Life Sciences Inc have?
Emmaus Life Sciences Inc has 70,188,260 shares outstanding.
What happened to Emmaus Life Sciences Inc’s price movement after its last earnings report?
Emmaus Life Sciences Inc reported an EPS of -$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Emmaus Life Sciences Inc?
Currently, no hedge funds are holding shares in EMMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Emmaus Life Sciences Inc
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
CDT Equity
―
Ownership Overview
15.29%
Insiders
0.08% Other Institutional Investors
84.63% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---